NasdaqGS:MDGLBiotechs
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After New Pfizer Partnership In Metabolic Liver Disease
Madrigal’s new Pfizer partnership puts MASH combinations in focus
Madrigal Pharmaceuticals (MDGL) just signed an exclusive global license agreement giving Pfizer rights to ervogastat, a clinical-stage oral DGAT-2 inhibitor. This agreement directly targets future combination approaches in metabolic liver disease.
The deal centers on DGAT-2’s role in triglyceride assembly and liver fat storage, an area closely linked to inflammation in MASH. Investors now have a new data point to watch as...